Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Today’s News

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Nov 12, 2024 1:53pm

89 Views

Post# 36308641

RE:RE:RE:RE:RE:Today’s News

Aww numbers, you feeling the pressure? Great news on the call, Pela keeps showing what it can do. You and the and the rest of the Backstreet Boys keep sowing that FUD but I'm more than happy. Dollar Cost Averaging at this point and it feels just lovely.

Can't take the heat, get outta the kitchen ladies.

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3